-
Sizzling Stocks: Vermillion (NASDAQ:VRML), Pfenex Inc. (NYSEMKT:PFNX), Bio-Path Holdings (NASDAQ:BPTH), Hexcel Corp. (NYSE:HXL), Ford Motor Company (NYSE:F)
On February 14, it was reported that, Vermillion, Inc. (NASDAQ:VRML), has been awarded ISO 13485:2003 from the British Standards Institution (BSI), one of the world’s leading certification bodies, for Vermillion’s quality management system. ISO 13485:2003 certification is the internationally recognized quality standard for medical devices and diagnostics. On Wednesday shares of Vermillion, Inc. (NASDAQ:VRML) closed…
-
Biotech Top Gainers: Alcobra (NASDAQ:ADHD), Pfenex Inc. (NYSEMKT:PFNX), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Can-Fite BioPharma (NYSEMKT:CANF), Actinium Pharmaceuticals (NYSEMKT:ATNM)
Alcobra Ltd. (NASDAQ:ADHD) announced Total operating expenses in the fourth quarter and fiscal year 2014 were $6.8 million and $33.1 million, respectively, compared with $5.6 million and $10.3 million in the fourth quarter and fiscal year 2013. Net operating expenses, excluding non-cash stock based compensation, in the fourth quarter and fiscal year 2014 were $6.0…
-
Stock Alert: Molycorp (NYSE:MCP), Pfenex Inc. (NYSEMKT:PFNX), Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT), Mesa Laboratories Inc. (NASDAQ:MLAB), Trevena (NASDAQ:TRVN)
On 2 February, Molycorp, Inc. (NYSE:MCP) reported that rare earth production in the fourth quarter of 2014 at its Mountain Pass, California facility increased year-on-year and nearly doubled that of the preceding quarter. Mountain Pass completed Q4 of 2014 with 1,328 metric tons (mt) of rare earth oxide (REO) equivalent production. That compares to 1,034…
-
What’s Hot: Pfenex Inc. (NYSEMKT:PFNX), Office Depot (NASDAQ:ODP), Rackspace Hosting (NYSE:RAX), TripAdvisor Inc. (NASDAQ:TRIP), Rite Aid Corporation (NYSE:RAD)
Hospira Inc. entered into an agreement with Pfenex Inc. (NYSEMKT:PFNX) for the exclusive development and global commercialization of a biosimilar of Lucentis (eye treatment), PF582, Pfenex’s lead biosimilar candidate. Shares of Pfenex jumped 15.9% following the announcement. On Wednesday shares of Pfenex Inc. (NYSEMKT:PFNX) closed at $9.75. Rigrodsky & Long, P.A. announces that it is…
-
Market Watch List: Pfenex Inc. (NYSEMKT:PFNX), NanoString Technologies (NASDAQ:NSTG), Verizon Communications Inc. (NYSE:VZ), MAXIMUS (NYSE:MMS), JA Solar Holdings (NASDAQ:JASO)
Pfenex Inc. (NYSE: PFNX) and Hospira (NYSE: HSP) announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex’s biosimilar candidate to Genentech’s LUCENTIS® (ranibizumab injection). LUCENTIS had estimated global sales of approximately $4 billion in 2014 and is part of the broader $6.7 billion intraocular anti-VEGF…
-
Morning Movers: Pfenex Inc. (NYSEMKT:PFNX), Citi Trends (NASDAQ:CTRN), Permian Basin Royalty Trust (NYSE:PBT), Regions Financial (NYSE:RF), Dover Downs Gaming & Entertainment (NYSE:DDE)
On 10 February, Pfenex Inc. (NYSEMKT:PFNX) and Hospira, Inc., (NYSE: HSP) announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex’s biosimilar candidate to Genentech’sLUCENTIS® (ranibizumab injection). On Wednesday shares of Pfenex Inc. (NYSEMKT:PFNX) closed at $9.75. Citi Trends, Inc. (NASDAQ:CTRN) reported unaudited sales results for…
-
Biotech Big Gainers: Synthetic Biologics Inc. (NYSEMKT:SYN), Amicus Therapeutics (NASDAQ:FOLD), Sangamo Biosciences Inc. (NASDAQ:SGMO), Idera Pharmaceuticals (NASDAQ:IDRA), Pfenex Inc. (NYSEMKT:PFNX)
Synthetic Biologics, Inc. (NYSEMKT:SYN) announced positive top-line results from a randomized, double-blind, placebo-controlled phase Ib study on its investigational oral beta-lactamase enzyme, SYN-004. On Wednesday shares of Synthetic Biologics Inc. (NYSEMKT:SYN) closed at $1.86. Amicus Therapeutics (NASDAQ:FOLD), highlighted results from preclinical studies of its next-generation Pompe ERT at WORLD Symposium™ 2015 in Orlando, Florida. Amicus…
-
Traders Buzz: Asterias BioTherapeutics (NYSEMKT:AST), Pfenex Inc. (NYSEMKT:PFNX), CommScope Holding Company (NASDAQ:COMM), NICE Systems (NASDAQ:NICE), Plains GP Holdings (NYSE:PAGP)
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) announced that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock. The Company raised $5.5 million in aggregate gross proceeds from the public offering and the private placement, which it intends to use for the continued development of product candidates through…
-
Biotech Top Gainers: Exelixis (NASDAQ:EXEL), Juno Therapeutics Inc. (NASDAQ:JUNO), Verastem (NASDAQ:VSTM), Amicus Therapeutics (NASDAQ:FOLD), Pfenex Inc. (NYSEMKT:PFNX)
Exelixis, Inc. (NASDAQ:EXEL) announced that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 24, 2015 after the markets close. On Tuesday shares of Exelixis, Inc. (NASDAQ:EXEL) closed at $2.19. Company’s sales growth for last 5 years was -23.30%. Juno Therapeutics (NASDAQ:JUNO) announced that it has entered into a…
-
Traders Are Gambling on: SouFun (NYSE:SFUN), LeapFrog Enterprises Inc. (NYSE:LF), Pfenex Inc. (NYSEMKT:PFNX), Achillion Pharmaceuticals (NASDAQ:ACHN), Sutor Technology Group Limited (NASDAQ:SUTR)
SouFun Holdings Ltd. (NYSE:SFUN) reported Q4 EPS of $0.21 beats by $0.07.Revenue of $223M (+2.7% Y/Y) beats by $15.8M. On Tuesday shares of SouFun Holdings Ltd. (NYSE:SFUN) closed at $6.65. Company’s sales growth for last 5 years was 43.70% and EPS growth for next 5 years is recorded as 8.92%. Faruqi & Faruqi, LLP, a…